MSD’s HIV / AIDS treatment ISENTRESS was designated as first line drug with no treatment-experienced HIV / AIDS patients
MSD’s HIV / AIDS treatment ISENTRESS was designated as first line drug with no treatment-experienced HIV / AIDS patients
(Yakup Shinmoon)
On Feb 10, MSD Korea announced that the HIV / AIDS treatment ISENTRESS (ingredient: raltegravil) was designated as first line drug with no treatment-experien...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
